株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ドラッグデリバリーにおけるナノテクノロジー:高い潜在性を満たすための技術改良と新たなアプローチ

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

発行 GBI Research 商品コード 146087
出版日 ページ情報 英文 77 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
ドラッグデリバリーにおけるナノテクノロジー:高い潜在性を満たすための技術改良と新たなアプローチ Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
出版日: 2010年12月31日 ページ情報: 英文 77 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

ナノ・ドラッグデリバリー市場は高い成長率をみせており、近い将来も急速に拡大すると期待されています。同市場は競争が激化し、ベンチャーキャピタルや政府による投資が行なわれており、将来的にはM&Aやライセンシング契約が大きな変化をもたらすでしょう。

当レポートでは、ナノによるドラッグデリバリー技術の応用動向と各社のケーススタディ、政府およびベンチャーキャピタルによる投資動向、欧米および日本の法規制動向、戦略的M&A動向などをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 ドラッグデリバリーにおけるナノテクノロジーの応用

  • 現在のナノ・ドラッグデリバリーの応用
  • 将来のナノ・ドラッグデリバリーの応用

第4章 ケーススタディ

  • Abraxis Bioscience, Inc
  • Nanospectra Biosciences
  • Calando Pharmaceuticals Inc
  • Starpharma Holdings Ltd.
  • Mersana Therapeutics
  • Elan Corporation

第5章 市場の特性

  • イントロダクション
  • 市場促進因子
  • 市場障壁
  • 機会とアンメットニーズ
  • FDAに認可されたナノ療法

第6章 動向分析

  • ナノテクノロジー研究開発のための政府資金援助の増加
  • シードおよび早期ベンチャーキャピタルの増加
  • USPTOにおけるナノテクノロジー製品の新たな登録カテゴリー
  • 新たなドラッグデリバリー法のニーズを促進するジェネリック化と新たなビジネスモデル

第7章 法規制環境

  • イントロダクション
  • 欧州
  • 米国
  • 日本

第8章 パイプライン分析

  • 概要
    • 相別パイプライン分析
  • 第9章 戦略的考察
  • 概要
  • 合併・買収
  • M&A取引サマリー
  • ライセンシング契約
  • 主なM&A取引サマリー

第10章 将来の参入企業

第11章 付録

図表

目次
Product Code: GBIHC043MR

Abstract

GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues in Nanotechnology in Drug Delivery market. The report provides a comprehensive insight into the role of Nanotechnology in Drug Delivery. The report also provides a detailed analysis of market characterization of nanotechnology in drug delivery market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the technological trends over the years in use of nanotechnology in drug delivery.

The nano-enabled drug delivery market has seen high growth in the market and is expected to grow at a faster rate in the near future. The market will witness increased competition, high investment from venture capitalists and government. The M&A and licensing landscape will see significant changes in the future. This is because the market is expected to become more lucrative.

The Nano-Enabled Market Represents Significant Opportunities and High Level of Unmet Needs

Nanotechnology in Drug Delivery Market, Opportunity and Unmet Needs, 2010

Source: GBI Research

The nano-enabled drug delivery market has plenty of opportunities and a high level of unmet need. Opportunities for creating a new drug delivery company are tremendous. Many small companies have launched the technology to develop novel methods for exploiting nanotechnologies in drug delivery. In the past, companies have been dedicated to the nano-enabled drug delivery that has been popping up all over the world.

The creation of new companies will not only increase the investment and market growth, but also increase the competition in the market place. In addition, the emergence of new companies will provide licensing and merger and acquisition (M&A) opportunities for larger pharmaceutical markets.

The market is also characterized by high levels of unmet need. This is primarily because development in this area is in its initial stages and has a significant number of unaddressed issues such as nanotoxicity, biological behavior and distribution pattern of nanoparticles. These unmet needs represent a significant opportunity for companies to explore.

In summary, high growth in the nano-enabled drug delivery markets will provide significant opportunities for companies.

Increased Investment and Emerging Business Models Will Support the Market Growth

The increasing investment in the nano-enabled drug delivery market has significantly driven the market. Funding for nanotechnology programs increased during the administration of George Bush.

The nanotechnology funding is expected to increase significantly in the future. Among all the major geographies, the European government is investing more in nanotechnology R&D. This suggests that there will be increased governmental support for nanotechnology R&D. In addition, increase in early stage venture capital will also affect the market positively.

Careful Approach of Regulator towards Nanotechnology is Negatively Affecting the Market

Challenges Facing Regulators Regarding Nanotechnology

Source: GBI Research

The toxicity increases due to increased surface area for the particle when the size is reduced. This gives rise to concerns about the possible negative impact on public health and environment due to increased use of nanotechnology enabled products. Nanotechnology is increasingly being employed in industries such as medicine, cosmetics, food, semiconductor devices, energy and telecommunications due to the advantages it provides over the conventional technology. As the use of nanotechnology progresses, the risk of exposure to the population also rises. This has led a cautious approach of regulators toward nanotechnology.

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues in Nanotechnology in Drug Delivery market. The report provides a comprehensive insight into the role of Nanotechnology in Drug Delivery. The report also provides a detailed analysis of market characterization of nanotechnology in drug delivery market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the technological trends over the years in use of nanotechnology in drug delivery.

Scope

The scope of the report includes:
• Detailed overview of Nanotechnology in Drug Delivery in pharmaceutical industry along with their use, efficiency and limitation.
• Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.
• Key market drivers and restraints shaping the Nanotechnology in Drug Delivery market.
• Competitive landscape analysis with competitive profiling of leading companies.
• Analysis of partnership deals from 2006 to 2010
• Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
• Develop better strategies for Nanotechnology in Drug Delivery market by understanding the market dynamics.
• Develop market-entry and market expansion strategies by identifying the key development area
• Understand the factors shaping the Nanotechnology in Drug Delivery
• For understanding the technological trends in the market.
• Identify the key players best positioned to take the advantage of the opportunities in the global market.
• Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 6
2 Nanotechnology in Drug Delivery - Introduction 7
2.1 Introduction 7
2.2 GBI Research Report Guidance 8
3 Application of Nanotechnology in Drug Delivery 9
3.1 Current Applications of Nano-enabled Drug Delivery 9
3.1.1 Nano-engineered drugs 9
3.1.2 Nano-carriers 10
3.2 Future Applications of Nano-enabled Drug Delivery 11
3.2.1 Gene and Vaccine Delivery 11
3.2.2 Controlled-Release Devices 12
3.2.3 Increased Biocompatibility 12
3.2.4 Improved Drug Bioavailability and Solubility 12
3.2.5 Applied Diagnosis, Etiology, Prognosis and Therapy (ADEPT) 12
3.2.6 Tissue Specific Delivery 12
4 Nanotechnology in Drug Delivery - Case Studies 13
4.1 Abraxis Bioscience, Inc. - Paclitaxel-Albumin Nanoparticles (Abraxane) 13
4.2 Nanospectra Biosciences- AuroShell Particles 13
4.3 Calando Pharmaceuticals, Inc. - RONDEL Technology 13
4.4 Starpharma Holdings, Ltd. - Dendrimer-Based VivaGel 14
4.5 Mersana Therapeutics: Fleximer - Camptothecin Conjugate 14
4.6 Elan Corporation - NanoCrystal Technology 14
5 Nanotechnology in Drug Delivery - Market Characterization 16
5.1 Introduction 16
5.2 Nano-enabled Drug Delivery Market Drivers 16
5.2.1 Clinical Benefits of Nano-enabled Drug delivery 16
5.2.2 Value Addition to Existing Pharmaceutical Products through Reformulation 16
5.2.3 Strong Pipeline Portfolio 16
5.3 Nano-Enabled Drug Delivery Market Barriers 17
5.3.1 Poor R&D Facilities and Time Gap between Research and Commercialization 17
5.3.2 Lack of Consistent Policy on Technology Transfer and Lack of Capacity to Produce Products 17
5.3.3 Regulatory Hindrance 17
5.4 Opportunity and Unmet Need - Drug Delivery 18
5.4.1 Opportunities 18
5.4.2 Unmet Need 18
5.5 Selected Nano-Enabled Therapeutics Approved by the FDA 20
5.5.1 Doxil (Caelyx) 20
5.5.2 Abraxane 21
5.5.3 AmBisome 22
5.5.4 Diprivan 23
5.5.5 Triglide 24
5.5.6 Myocet 25
5.5.7 DepoCyt 26
5.5.8 DaunoXome 27
5.5.9 Estrasorb 27
5.5.10 Macugen 28
5.5.11 Abelcet 29
5.5.12 Adagen 30
5.5.13 Pegasys 30
5.5.14 Somavert 32
5.5.15 Neulasta 33
5.5.16 Copaxone 34
5.5.17 Amphotec 35
5.5.18 PegIntron 35
5.5.19 Oncaspar 37
5.5.20 Epaxal 38
5.5.21 Elestrin 38
6 Nanotechnology in Drug Delivery - Trend Analysis 40
6.1 Increasing Government Funding for Nanotechnology R&D 40
6.2 Increasing Seed and Early-Stage Venture Capital 40
6.3 Creation of a New Registration Category for Nanotechnology Products within the USPTO 40
6.4 Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery Methods 41
7 Nanotechnology in Drug Delivery - Regulatory Landscape 42
7.1 Introduction 42
7.2 Europe 44
7.2.1 REACH Regulation 44
7.2.2 European Medicines Agency 46
7.3 The US 46
7.3.1 Environment Protection Agency 46
7.3.2 Food and Drug Administration 47
7.3.3 National Institute of Occupational Safety and Health 47
7.4 Japan 48
8 Nanotechnology in Drug Delivery - Pipeline Analysis 49
8.1 Overview 49
8.1.1 Pipeline Analysis by Phase 50
9 Nanotechnology in Drug Delivery - Strategic Consolidations 55
9.1 Overview 55
9.2 Mergers and Acquisitions 55
9.2.1 Mergers and Acquisitions by Geography 55
9.2.2 Mergers and Acquisitions by Deal value 56
9.2.3 Mergers and Acquisition Analysis by Deal Type 57
9.3 Summary of Major M&A Deals 58
9.3.1 AstraZeneca Acquires MedImmune 58
9.3.2 Pfizer Completes Acquisition of Wyeth 58
9.3.3 Celgene Announces To Acquire Abraxis BioScience 58
9.3.4 Amgen Acquires Abgenix 59
9.3.5 Teva Pharmaceutical Acquires Ivax 59
9.4 Licensing Agreement 60
9.4.1 Deals by Year of Consolidations 60
9.4.2 Deals by Geography 61
9.4.3 Deals by Deal value 62
9.5 Summary of Major M&A Deals 62
9.5.1 AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept 62
9.5.2 AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals 63
9.5.3 Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme 63
9.5.4 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca 63
9.5.5 Abraxis Enters Into License Agreement With ProMetic Life Sciences 64
10 Nanotechnology in Drug Delivery - Future Players 65
10.1 Overview 65
10.2 Abraxis Bioscience (Abraxis) 66
10.2.1 Overview 66
10.2.2 Business Description 66
10.2.3 Product Portfolio 67
10.3 AlphaRx Corporation 68
10.3.1 Overview 68
10.3.2 Business Description 68
10.3.3 Product Portfolio 69
10.4 Camurus AB 69
10.4.1 Overview 69
10.4.2 Product Portfolio 70
10.5 Eurand 70
10.5.1 Overview 70
10.5.2 Business Description 70
10.5.3 Product Portfolio 71
10.6 NanoBio Corporation 71
10.6.1 Overview 71
10.6.2 Product Portfolio 72
10.7 NanoCarrier 72
10.7.1 Overview 72
10.7.2 Product Portfolio 73
11 Nanaotechnology in Drug Delivery - Appendix 74
11.1 Market Definitions 74
11.2 Abbreviations 74
11.3 Research Methodology 75
11.3.1 Coverage 76
11.3.2 Secondary Research 76
11.3.3 Primary Research 76
11.3.4 Expert Panel Validation 77
11.4 Contact Us 77
11.5 Disclaimer 77
11.6 Sources 77

1.1 List of Tables
Table 1: Elan Pharmaceutical, Drugs Based on NanoCrystal Technology, 2010 15
Table 2: Nanotechnology in Drug Delivery, Global, Regulatory Filing Clinical Pipeline, 2010 50
Table 3: Nanotechnology in Drug Delivery, Global, Phase III Clinical Pipeline, 2010 51
Table 4: Nanotechnology in Drug Delivery, Global, Phase II Clinical Pipeline, 2010 51
Table 5: Nanotechnology in Drug Delivery, Global, Phase I Clinical Pipeline, 2010 52
Table 6: Nanotechnology in Drug Delivery, Global, Preclinical Pipeline, 2010 53
Table 7: Nanotechnology in Drug Delivery, Global, Discovery Pipeline, 2010 54
Table 8: Abraxis BioScience, Inc., Nano-Enabled Drug Delivery Pipeline Products, 2010 67
Table 9: AlphaRx Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 69
Table 10: Camurus AB, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 70
Table 11: Eurand, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 71
Table 12: NanoBio Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 72
Table 13: NanoCarrier, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 73

1.2 List of Figures
Figure 1: Nanotechnology in Drug Delivery, Comparison of General and Nano-enabled Drugs, 2010 7
Figure 2: Nanotechnology in Drug Delivery, Current Application of Nanotechnology in the Pharmaceutical Industry, 2010 9
Figure 3: Nanotechnology in Drug Delivery, Future Application of Nanotechnology in Drug Pharmaceutical Industry, 2010 11
Figure 4: Nanotechnology in Drug Delivery, Global, Driver and Restraints, 2010 17
Figure 5: Nanotechnology in Drug Delivery, Opportunity and Unmet Needs, 2010 19
Figure 6: Nanotechnology in Drug Delivery, Trend Analysis, 2010 40
Figure 7: Nanotechnology in Drug Delivery, Challenges Facing Regulators Regarding Nanotechnology 43
Figure 8: Nanotechnology in Drug Delivery, Global, Pipeline by Therapy Area (%), 2010 49
Figure 9: Nanotechnology in Drug Delivery, Global, Pipeline by Phase (%), 2010 50
Figure 10: Nanotechnology in Drug Delivery, Global, M&A Deals by Geography (%), (2006-2010) 55
Figure 11: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Value (%), 2006-2010 56
Figure 12: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Type (%), 2006-2010 57
Figure 13: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Years of Consolidation (%), 2006-2010 60
Figure 14: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Geography (%), 2006-2010 61
Figure 15: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Deals Value (%), 2006-2010 62
Figure 16: Nanotechnology in Drug Delivery, Global, Clinical Pipeline by Company, 2010 65

Back to Top